| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 15 | 2022 | 233 | 4.500 |
Why?
|
| MicroRNAs | 10 | 2022 | 447 | 1.670 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2020 | 50 | 1.420 |
Why?
|
| Pulmonary Embolism | 2 | 2020 | 253 | 1.170 |
Why?
|
| Critical Care | 6 | 2021 | 263 | 1.130 |
Why?
|
| Patient Readmission | 3 | 2017 | 267 | 1.050 |
Why?
|
| Pathology, Clinical | 2 | 2022 | 16 | 1.040 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2020 | 100 | 0.990 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2022 | 2 | 0.930 |
Why?
|
| Clinical Laboratory Services | 1 | 2022 | 3 | 0.920 |
Why?
|
| Electronic Prescribing | 1 | 2022 | 9 | 0.910 |
Why?
|
| Medical Order Entry Systems | 1 | 2021 | 24 | 0.870 |
Why?
|
| Endothelial Cells | 3 | 2020 | 384 | 0.840 |
Why?
|
| Electronic Health Records | 5 | 2022 | 373 | 0.820 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2021 | 88 | 0.810 |
Why?
|
| Physiological Phenomena | 1 | 2020 | 2 | 0.800 |
Why?
|
| Circulating MicroRNA | 1 | 2020 | 9 | 0.790 |
Why?
|
| Intensive Care Units | 9 | 2022 | 344 | 0.780 |
Why?
|
| Antifibrinolytic Agents | 1 | 2020 | 52 | 0.770 |
Why?
|
| Information Storage and Retrieval | 1 | 2020 | 49 | 0.760 |
Why?
|
| Humans | 56 | 2022 | 68502 | 0.760 |
Why?
|
| International Normalized Ratio | 1 | 2019 | 23 | 0.750 |
Why?
|
| Point-of-Care Testing | 1 | 2019 | 12 | 0.740 |
Why?
|
| Automation, Laboratory | 1 | 2019 | 5 | 0.730 |
Why?
|
| von Willebrand Factor | 1 | 2019 | 47 | 0.730 |
Why?
|
| Shock | 1 | 2019 | 28 | 0.730 |
Why?
|
| Critical Care Outcomes | 1 | 2018 | 1 | 0.710 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 772 | 0.690 |
Why?
|
| Physicians | 1 | 2022 | 324 | 0.680 |
Why?
|
| Thrombophilia | 1 | 2017 | 21 | 0.670 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 114 | 0.660 |
Why?
|
| Blood Platelets | 1 | 2019 | 284 | 0.660 |
Why?
|
| Triage | 1 | 2018 | 109 | 0.650 |
Why?
|
| Pericytes | 5 | 2022 | 81 | 0.630 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 2016 | 12 | 0.630 |
Why?
|
| Length of Stay | 4 | 2018 | 780 | 0.620 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 124 | 0.610 |
Why?
|
| Critical Illness | 5 | 2021 | 191 | 0.590 |
Why?
|
| Medically Underserved Area | 1 | 2016 | 85 | 0.590 |
Why?
|
| Benzodiazepines | 1 | 2016 | 130 | 0.590 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 12 | 0.570 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 18 | 0.570 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 1291 | 0.570 |
Why?
|
| Shock, Septic | 1 | 2015 | 101 | 0.570 |
Why?
|
| Risk Adjustment | 1 | 2015 | 49 | 0.560 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 3 | 2022 | 106 | 0.540 |
Why?
|
| Respiratory Insufficiency | 3 | 2021 | 76 | 0.520 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 247 | 0.520 |
Why?
|
| Patient Transfer | 3 | 2021 | 86 | 0.510 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 438 | 0.500 |
Why?
|
| Quality Improvement | 4 | 2021 | 413 | 0.470 |
Why?
|
| Health Status Disparities | 1 | 2016 | 326 | 0.460 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 498 | 0.460 |
Why?
|
| Depressive Disorder, Major | 1 | 2016 | 438 | 0.440 |
Why?
|
| Age Factors | 6 | 2020 | 1857 | 0.440 |
Why?
|
| Lung | 5 | 2021 | 849 | 0.420 |
Why?
|
| Mammaplasty | 3 | 2018 | 41 | 0.420 |
Why?
|
| Cohort Studies | 4 | 2020 | 2356 | 0.410 |
Why?
|
| Organ Dysfunction Scores | 2 | 2021 | 13 | 0.400 |
Why?
|
| Female | 22 | 2022 | 37990 | 0.370 |
Why?
|
| Databases, Factual | 6 | 2018 | 621 | 0.360 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 77 | 0.360 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 1852 | 0.360 |
Why?
|
| Veterans | 1 | 2017 | 904 | 0.360 |
Why?
|
| Endothelial Progenitor Cells | 2 | 2019 | 15 | 0.350 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2019 | 101 | 0.350 |
Why?
|
| Middle Aged | 17 | 2022 | 21116 | 0.340 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 848 | 0.340 |
Why?
|
| Retrospective Studies | 12 | 2022 | 7263 | 0.330 |
Why?
|
| Arterial Pressure | 2 | 2019 | 46 | 0.330 |
Why?
|
| Oxygen | 2 | 2019 | 386 | 0.320 |
Why?
|
| Male | 17 | 2022 | 37252 | 0.320 |
Why?
|
| Vital Signs | 2 | 2018 | 19 | 0.320 |
Why?
|
| Breast Neoplasms | 5 | 2017 | 1531 | 0.310 |
Why?
|
| United States | 8 | 2021 | 7333 | 0.310 |
Why?
|
| Data Collection | 2 | 2019 | 420 | 0.290 |
Why?
|
| Aged | 15 | 2022 | 14841 | 0.280 |
Why?
|
| Logistic Models | 4 | 2017 | 1419 | 0.280 |
Why?
|
| Medicaid | 3 | 2017 | 301 | 0.280 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1046 | 0.260 |
Why?
|
| Respiration, Artificial | 3 | 2022 | 190 | 0.260 |
Why?
|
| Odds Ratio | 2 | 2016 | 880 | 0.240 |
Why?
|
| Medicare | 2 | 2016 | 316 | 0.240 |
Why?
|
| Blood Coagulation Tests | 2 | 2022 | 31 | 0.240 |
Why?
|
| Breast | 2 | 2017 | 137 | 0.240 |
Why?
|
| South Carolina | 4 | 2020 | 2750 | 0.240 |
Why?
|
| Dabigatran | 1 | 2022 | 35 | 0.220 |
Why?
|
| Laboratories | 1 | 2022 | 44 | 0.220 |
Why?
|
| Rivaroxaban | 1 | 2022 | 26 | 0.220 |
Why?
|
| Patient Care | 1 | 2022 | 61 | 0.220 |
Why?
|
| Mice | 12 | 2022 | 8453 | 0.210 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2017 | 32 | 0.210 |
Why?
|
| Thrombelastography | 1 | 2021 | 19 | 0.210 |
Why?
|
| Hemostasis | 1 | 2021 | 32 | 0.210 |
Why?
|
| RNA, Long Noncoding | 1 | 2022 | 54 | 0.210 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 45 | 0.210 |
Why?
|
| Exosomes | 2 | 2019 | 44 | 0.210 |
Why?
|
| Guideline Adherence | 2 | 2015 | 284 | 0.210 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 4842 | 0.210 |
Why?
|
| Hospital Mortality | 3 | 2022 | 384 | 0.200 |
Why?
|
| Data Compression | 1 | 2020 | 5 | 0.200 |
Why?
|
| Animals | 13 | 2022 | 20811 | 0.200 |
Why?
|
| Patient Safety | 1 | 2022 | 202 | 0.200 |
Why?
|
| Biomarkers | 5 | 2018 | 1593 | 0.200 |
Why?
|
| Glioma | 1 | 2021 | 140 | 0.200 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 69 | 0.200 |
Why?
|
| Umbilical Arteries | 1 | 2019 | 9 | 0.190 |
Why?
|
| Drug Approval | 1 | 2020 | 50 | 0.190 |
Why?
|
| Microvessels | 1 | 2020 | 43 | 0.190 |
Why?
|
| Blood Gas Analysis | 1 | 2019 | 41 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 116 | 0.190 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 938 | 0.190 |
Why?
|
| Patient Acuity | 1 | 2019 | 17 | 0.190 |
Why?
|
| Knee Joint | 1 | 2020 | 115 | 0.190 |
Why?
|
| Respiratory Therapy | 1 | 2019 | 24 | 0.190 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 131 | 0.190 |
Why?
|
| Chemokines | 1 | 2020 | 119 | 0.190 |
Why?
|
| Preoperative Period | 1 | 2019 | 50 | 0.190 |
Why?
|
| Reference Standards | 1 | 2019 | 115 | 0.180 |
Why?
|
| Cell Line | 2 | 2021 | 1751 | 0.180 |
Why?
|
| Caspase 1 | 1 | 2019 | 22 | 0.180 |
Why?
|
| Hemoglobins | 1 | 2019 | 120 | 0.180 |
Why?
|
| Neutrophils | 1 | 2020 | 204 | 0.180 |
Why?
|
| Professional-Family Relations | 1 | 2019 | 45 | 0.180 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2018 | 11 | 0.180 |
Why?
|
| Probability | 1 | 2019 | 244 | 0.180 |
Why?
|
| Family | 1 | 2021 | 293 | 0.180 |
Why?
|
| Acute Lung Injury | 1 | 2019 | 35 | 0.180 |
Why?
|
| History, 21st Century | 1 | 2019 | 126 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 174 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2022 | 442 | 0.170 |
Why?
|
| Drug Carriers | 1 | 2019 | 90 | 0.170 |
Why?
|
| Medical Informatics | 1 | 2019 | 71 | 0.170 |
Why?
|
| Body Temperature | 1 | 2018 | 116 | 0.170 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 2264 | 0.170 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2018 | 72 | 0.170 |
Why?
|
| History, 20th Century | 1 | 2019 | 248 | 0.170 |
Why?
|
| Electroencephalography | 1 | 2020 | 418 | 0.170 |
Why?
|
| Hypothermia, Induced | 1 | 2018 | 93 | 0.170 |
Why?
|
| Insurance, Health | 2 | 2016 | 200 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2020 | 146 | 0.170 |
Why?
|
| Equipment Design | 1 | 2019 | 500 | 0.160 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2019 | 282 | 0.160 |
Why?
|
| Hypertrophy | 1 | 2017 | 89 | 0.160 |
Why?
|
| Prognosis | 3 | 2020 | 2093 | 0.160 |
Why?
|
| Infant, Premature | 1 | 2019 | 284 | 0.160 |
Why?
|
| Patient Admission | 1 | 2018 | 99 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 503 | 0.160 |
Why?
|
| Cell Movement | 1 | 2020 | 630 | 0.160 |
Why?
|
| Incidence | 3 | 2017 | 1581 | 0.160 |
Why?
|
| Heart Rate | 1 | 2019 | 568 | 0.160 |
Why?
|
| Adult | 9 | 2021 | 21373 | 0.150 |
Why?
|
| Hospitalization | 3 | 2022 | 976 | 0.150 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 557 | 0.150 |
Why?
|
| Software | 1 | 2019 | 419 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 158 | 0.150 |
Why?
|
| Plasma | 1 | 2015 | 58 | 0.150 |
Why?
|
| Social Class | 1 | 2016 | 127 | 0.150 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 2542 | 0.150 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2015 | 6 | 0.140 |
Why?
|
| Hepatorenal Syndrome | 1 | 2015 | 16 | 0.140 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2015 | 19 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2019 | 254 | 0.140 |
Why?
|
| Decision Making | 1 | 2019 | 410 | 0.140 |
Why?
|
| Mastectomy, Segmental | 1 | 2015 | 63 | 0.140 |
Why?
|
| Inflammation | 2 | 2019 | 1029 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 1 | 2015 | 107 | 0.140 |
Why?
|
| Documentation | 1 | 2015 | 83 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2016 | 113 | 0.140 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 1752 | 0.130 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2015 | 99 | 0.130 |
Why?
|
| Algorithms | 2 | 2020 | 1194 | 0.130 |
Why?
|
| Hospitals | 1 | 2017 | 265 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 192 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 219 | 0.130 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2014 | 21 | 0.130 |
Why?
|
| Sex Factors | 2 | 2016 | 1265 | 0.130 |
Why?
|
| Survivors | 1 | 2017 | 254 | 0.130 |
Why?
|
| Mitral Valve | 1 | 2015 | 166 | 0.130 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 51 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2016 | 403 | 0.130 |
Why?
|
| Syndecan-2 | 1 | 2013 | 2 | 0.130 |
Why?
|
| Comorbidity | 2 | 2016 | 1425 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 100 | 0.130 |
Why?
|
| Macrophages, Alveolar | 1 | 2013 | 34 | 0.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2015 | 164 | 0.120 |
Why?
|
| Risk Factors | 4 | 2017 | 5718 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1139 | 0.120 |
Why?
|
| Time Factors | 3 | 2019 | 4650 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2015 | 737 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2019 | 1447 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2021 | 3702 | 0.120 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 126 | 0.120 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2013 | 66 | 0.120 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2012 | 4 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2016 | 384 | 0.120 |
Why?
|
| Quality of Life | 1 | 2021 | 1514 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 232 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 234 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 439 | 0.110 |
Why?
|
| Infant | 4 | 2019 | 2891 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1548 | 0.110 |
Why?
|
| Pathology, Surgical | 1 | 2011 | 4 | 0.110 |
Why?
|
| Mice, Knockout | 3 | 2022 | 1691 | 0.110 |
Why?
|
| Pyridones | 2 | 2022 | 40 | 0.110 |
Why?
|
| Pulmonary Emphysema | 1 | 2012 | 71 | 0.110 |
Why?
|
| DNA Damage | 1 | 2012 | 190 | 0.110 |
Why?
|
| Medical Records | 1 | 2011 | 121 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2077 | 0.100 |
Why?
|
| Pyrazoles | 2 | 2022 | 190 | 0.100 |
Why?
|
| Cytokines | 3 | 2020 | 866 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2021 | 1505 | 0.100 |
Why?
|
| Hospitals, Community | 2 | 2020 | 64 | 0.100 |
Why?
|
| Young Adult | 3 | 2017 | 5708 | 0.090 |
Why?
|
| Incidental Findings | 1 | 2009 | 42 | 0.090 |
Why?
|
| Interdisciplinary Communication | 2 | 2020 | 93 | 0.090 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 74 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 207 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2019 | 2453 | 0.090 |
Why?
|
| Cecum | 2 | 2019 | 39 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 798 | 0.090 |
Why?
|
| Ligation | 2 | 2019 | 83 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2022 | 356 | 0.090 |
Why?
|
| Program Development | 2 | 2020 | 240 | 0.090 |
Why?
|
| Leadership | 2 | 2020 | 135 | 0.090 |
Why?
|
| Evidence-Based Practice | 2 | 2020 | 146 | 0.090 |
Why?
|
| Carcinoma | 1 | 2009 | 215 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2019 | 3185 | 0.080 |
Why?
|
| Adolescent | 5 | 2019 | 8903 | 0.080 |
Why?
|
| Lipopolysaccharides | 2 | 2019 | 455 | 0.080 |
Why?
|
| Vermont | 2 | 2017 | 21 | 0.080 |
Why?
|
| Genetic Markers | 2 | 2018 | 144 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2022 | 1026 | 0.070 |
Why?
|
| Hyperplasia | 2 | 2017 | 89 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2018 | 681 | 0.060 |
Why?
|
| Reoperation | 2 | 2015 | 467 | 0.060 |
Why?
|
| Child | 3 | 2019 | 6400 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2016 | 7026 | 0.060 |
Why?
|
| Hemoglobin Subunits | 1 | 2022 | 4 | 0.060 |
Why?
|
| Health Facilities | 1 | 2022 | 35 | 0.060 |
Why?
|
| Partial Thromboplastin Time | 1 | 2022 | 57 | 0.060 |
Why?
|
| Victoria | 1 | 2021 | 8 | 0.050 |
Why?
|
| Antithrombins | 1 | 2022 | 32 | 0.050 |
Why?
|
| Monte Carlo Method | 1 | 2021 | 124 | 0.050 |
Why?
|
| Fourier Analysis | 1 | 2020 | 31 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2022 | 411 | 0.050 |
Why?
|
| Evoked Potentials | 1 | 2020 | 58 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 498 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2021 | 102 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2022 | 189 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2018 | 2670 | 0.050 |
Why?
|
| Catheters | 1 | 2019 | 39 | 0.050 |
Why?
|
| RNA Interference | 1 | 2020 | 266 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2021 | 237 | 0.050 |
Why?
|
| Escherichia coli K12 | 1 | 2019 | 9 | 0.050 |
Why?
|
| HMGB1 Protein | 1 | 2019 | 23 | 0.050 |
Why?
|
| Interleukin-18 | 1 | 2019 | 16 | 0.050 |
Why?
|
| Peroxidase | 1 | 2019 | 40 | 0.050 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2019 | 21 | 0.050 |
Why?
|
| Systole | 1 | 2019 | 149 | 0.050 |
Why?
|
| Punctures | 1 | 2019 | 35 | 0.050 |
Why?
|
| Pyroptosis | 1 | 2018 | 8 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2016 | 2004 | 0.050 |
Why?
|
| New Zealand | 1 | 2018 | 28 | 0.050 |
Why?
|
| Trachea | 1 | 2019 | 48 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 244 | 0.040 |
Why?
|
| Acetylglucosamine | 1 | 2019 | 44 | 0.040 |
Why?
|
| Gestational Age | 1 | 2019 | 389 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 209 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 196 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2020 | 432 | 0.040 |
Why?
|
| Capillary Permeability | 1 | 2018 | 69 | 0.040 |
Why?
|
| Fever | 1 | 2018 | 96 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 346 | 0.040 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2017 | 1 | 0.040 |
Why?
|
| Cardiovascular System | 1 | 2018 | 85 | 0.040 |
Why?
|
| Australia | 1 | 2018 | 235 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 392 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2019 | 221 | 0.040 |
Why?
|
| Hypertension | 2 | 2018 | 1531 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2018 | 167 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 219 | 0.040 |
Why?
|
| Cognition | 1 | 2022 | 510 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2020 | 2684 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2019 | 368 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2018 | 114 | 0.040 |
Why?
|
| Rural Population | 1 | 2020 | 397 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 371 | 0.040 |
Why?
|
| Florida | 1 | 2017 | 221 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2019 | 951 | 0.040 |
Why?
|
| Aortic Valve Stenosis | 1 | 2018 | 177 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 90 | 0.040 |
Why?
|
| Health Status | 1 | 2019 | 429 | 0.040 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 113 | 0.040 |
Why?
|
| Cell Communication | 1 | 2016 | 116 | 0.040 |
Why?
|
| Midodrine | 1 | 2015 | 7 | 0.040 |
Why?
|
| Octreotide | 1 | 2015 | 21 | 0.040 |
Why?
|
| Models, Biological | 1 | 2020 | 980 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 1054 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 581 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 85 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2016 | 105 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 33 | 0.040 |
Why?
|
| Pathology | 1 | 2015 | 17 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 114 | 0.040 |
Why?
|
| England | 1 | 2015 | 64 | 0.040 |
Why?
|
| Learning Curve | 1 | 2015 | 20 | 0.040 |
Why?
|
| Tobacco | 1 | 2016 | 161 | 0.040 |
Why?
|
| Creatinine | 1 | 2015 | 243 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2015 | 275 | 0.030 |
Why?
|
| Cholesterol | 1 | 2016 | 331 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 60 | 0.030 |
Why?
|
| Homeostasis | 1 | 2016 | 291 | 0.030 |
Why?
|
| New Hampshire | 1 | 2014 | 6 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 349 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2014 | 47 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 61 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2013 | 15 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 343 | 0.030 |
Why?
|
| Hydroxyproline | 1 | 2013 | 33 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 536 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 328 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 53 | 0.030 |
Why?
|
| Bleomycin | 1 | 2013 | 67 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 144 | 0.030 |
Why?
|
| Caveolin 1 | 1 | 2013 | 59 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 807 | 0.030 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2012 | 23 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1609 | 0.030 |
Why?
|
| Stem Cells | 1 | 2014 | 248 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 753 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 301 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 951 | 0.030 |
Why?
|
| DNA Repair | 1 | 2012 | 127 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 127 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 320 | 0.030 |
Why?
|
| Brain | 1 | 2022 | 2171 | 0.030 |
Why?
|
| Registries | 1 | 2014 | 730 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3256 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 696 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2015 | 656 | 0.020 |
Why?
|
| Heart Failure | 1 | 2018 | 1179 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 1074 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 1449 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2015 | 1615 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1640 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 2779 | 0.020 |
Why?
|